Baidu
map

Cancer Cell:癌细胞可以高效代谢果糖——急性髓细胞白血病研究的新发现

2016-10-16 佚名 麦特绘谱

上海交大附属第六人民医院转化医学中心贾伟教授课题组在与上海血液学研究所陈赛娟教授课题组的合作研究中发现,急性髓细胞白血病(AML)细胞具有极强的果糖代谢能力,而活跃的果糖代谢促进白血病的恶性进展。这项研究于2016年10月13日在线发表于癌症研究领域顶级学术期刊Cancer Cell杂志(链接为:http://www.cell.com/cancer-cell/fulltext/S1535- 610

上海交大附属第六人民医院转化医学中心贾伟教授课题组在与上海血液学研究所陈赛娟教授课题组的合作研究中发现,急性髓细胞白血病(AML)细胞具有极强的果糖代谢能力,而活跃的果糖代谢促进白血病的恶性进展。这项研究于2016年10月13日在线发表于癌症研究领域顶级学术期刊Cancer Cell杂志(链接为:http://www.cell.com/cancer-cell/fulltext/S1535- 6108(16)30441-X),研究论文的题目是“Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential”。贾伟教授和陈赛娟教授是这篇论文的共同通讯作者。陈文连博士、王月英博士和赵爱华博士为共同第一作者。

上述两个课题组合作,于2014年在国际学术期刊BLOOD(《血液》杂志)上发表了急性髓细胞白血病代谢组学的研究工作。研究发现AML患者整体代谢谱出现显著变化,通过自上而下(Top-down approach)的系统生物学研究思路,研究团队发现AML患者的糖酵解代谢水平非常活跃,而且患者的糖酵解代谢活性越高,其生存就越差。研究团队还发现,活跃的糖酵解代谢可显著降低AML细胞对化疗药阿糖胞苷的敏感性。研究人员在后续的工作中观察到,AML细胞异常活跃的糖酵解代谢可导致骨髓微环境中葡萄糖水平严重不足,而这种情况下AML细胞如何保持足量的碳源摄取以维持细胞的恶性增殖可能是一个十分重要的癌症代谢新机制。随着研究的进一步深入,他们获得了一个重要发现:在葡萄糖缺乏的情况下,AML细胞可启动一个替代机制转而利用果糖。果糖是人体血液系统中的第二大血糖,它的细胞转运由SLC2A5基因编码的GLUT5蛋白转运子介导。



研究团队发现,AML细胞表达的SLC2A5基因水平越高(即利用果糖的能力越强),则患者的预后越差。使用RNA沉默技术干扰AML细胞的SLC2A5基因表达,可显著降低细胞对果糖的摄取以及果糖诱导的细胞增殖。





在此发现的基础上,研究团队使用了一个小分子药物来特异性地阻断果糖的跨膜转运,这个抑制果糖利用的措施可以在体外细胞模型中显著抑制细胞的恶性增殖和浸润。而在AML动物模型中,使用该小分子药物阻断果糖的AML细胞跨膜转运可显著改善小鼠的白血病症状并延长小鼠的生存。值得关注的是,该小分子药物可与化疗药阿糖胞苷协同作用,进一步改善治疗效果。



这项研究工作揭示:除了葡萄糖之外,果糖是AML细胞的另外一个重要能源物质。负责果糖转运和利用的蛋白转运子GLUT5,是治疗AML的一个新的靶点。这样一个特征性的果糖代谢表型很可能存在于AML以外的别的肿瘤细胞中,而针对GLUT5的小分子化学药物或者抗体药物,有望与目前的常用肿瘤化疗药物(如阿糖胞苷)联合使用,极大地改善癌症患者的治疗效果。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1921142, encodeId=22f51921142cc, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Dec 15 14:04:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822159, encodeId=e169182215903, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Sep 05 06:04:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959846, encodeId=4d25195984679, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 14 18:04:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780694, encodeId=60b01e80694c8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Dec 10 08:04:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869587, encodeId=258c186958e71, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 22 07:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151766, encodeId=2c1b151e666b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:29 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151765, encodeId=dd83151e6592, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:23 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149566, encodeId=1b87149566c9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:09 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149565, encodeId=3d7114956507, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:04 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252146, encodeId=e440125214688, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Oct 18 05:04:00 CST 2016, time=2016-10-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1921142, encodeId=22f51921142cc, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Dec 15 14:04:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822159, encodeId=e169182215903, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Sep 05 06:04:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959846, encodeId=4d25195984679, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 14 18:04:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780694, encodeId=60b01e80694c8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Dec 10 08:04:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869587, encodeId=258c186958e71, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 22 07:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151766, encodeId=2c1b151e666b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:29 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151765, encodeId=dd83151e6592, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:23 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149566, encodeId=1b87149566c9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:09 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149565, encodeId=3d7114956507, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:04 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252146, encodeId=e440125214688, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Oct 18 05:04:00 CST 2016, time=2016-10-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1921142, encodeId=22f51921142cc, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Dec 15 14:04:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822159, encodeId=e169182215903, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Sep 05 06:04:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959846, encodeId=4d25195984679, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 14 18:04:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780694, encodeId=60b01e80694c8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Dec 10 08:04:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869587, encodeId=258c186958e71, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 22 07:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151766, encodeId=2c1b151e666b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:29 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151765, encodeId=dd83151e6592, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:23 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149566, encodeId=1b87149566c9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:09 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149565, encodeId=3d7114956507, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:04 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252146, encodeId=e440125214688, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Oct 18 05:04:00 CST 2016, time=2016-10-18, status=1, ipAttribution=)]
    2017-04-14 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=1921142, encodeId=22f51921142cc, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Dec 15 14:04:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822159, encodeId=e169182215903, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Sep 05 06:04:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959846, encodeId=4d25195984679, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 14 18:04:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780694, encodeId=60b01e80694c8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Dec 10 08:04:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869587, encodeId=258c186958e71, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 22 07:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151766, encodeId=2c1b151e666b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:29 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151765, encodeId=dd83151e6592, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:23 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149566, encodeId=1b87149566c9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:09 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149565, encodeId=3d7114956507, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:04 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252146, encodeId=e440125214688, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Oct 18 05:04:00 CST 2016, time=2016-10-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1921142, encodeId=22f51921142cc, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Dec 15 14:04:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822159, encodeId=e169182215903, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Sep 05 06:04:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959846, encodeId=4d25195984679, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 14 18:04:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780694, encodeId=60b01e80694c8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Dec 10 08:04:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869587, encodeId=258c186958e71, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 22 07:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151766, encodeId=2c1b151e666b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:29 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151765, encodeId=dd83151e6592, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:23 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149566, encodeId=1b87149566c9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:09 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149565, encodeId=3d7114956507, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:04 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252146, encodeId=e440125214688, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Oct 18 05:04:00 CST 2016, time=2016-10-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1921142, encodeId=22f51921142cc, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Dec 15 14:04:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822159, encodeId=e169182215903, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Sep 05 06:04:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959846, encodeId=4d25195984679, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 14 18:04:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780694, encodeId=60b01e80694c8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Dec 10 08:04:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869587, encodeId=258c186958e71, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 22 07:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151766, encodeId=2c1b151e666b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:29 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151765, encodeId=dd83151e6592, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:23 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149566, encodeId=1b87149566c9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:09 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149565, encodeId=3d7114956507, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:04 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252146, encodeId=e440125214688, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Oct 18 05:04:00 CST 2016, time=2016-10-18, status=1, ipAttribution=)]
    2016-10-28 1de2495dm19(暂无匿称)

    继续关注

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1921142, encodeId=22f51921142cc, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Dec 15 14:04:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822159, encodeId=e169182215903, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Sep 05 06:04:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959846, encodeId=4d25195984679, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 14 18:04:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780694, encodeId=60b01e80694c8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Dec 10 08:04:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869587, encodeId=258c186958e71, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 22 07:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151766, encodeId=2c1b151e666b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:29 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151765, encodeId=dd83151e6592, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:23 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149566, encodeId=1b87149566c9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:09 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149565, encodeId=3d7114956507, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:04 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252146, encodeId=e440125214688, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Oct 18 05:04:00 CST 2016, time=2016-10-18, status=1, ipAttribution=)]
    2016-10-28 1de2495dm19(暂无匿称)

    继续学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1921142, encodeId=22f51921142cc, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Dec 15 14:04:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822159, encodeId=e169182215903, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Sep 05 06:04:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959846, encodeId=4d25195984679, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 14 18:04:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780694, encodeId=60b01e80694c8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Dec 10 08:04:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869587, encodeId=258c186958e71, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 22 07:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151766, encodeId=2c1b151e666b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:29 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151765, encodeId=dd83151e6592, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:23 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149566, encodeId=1b87149566c9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:09 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149565, encodeId=3d7114956507, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:04 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252146, encodeId=e440125214688, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Oct 18 05:04:00 CST 2016, time=2016-10-18, status=1, ipAttribution=)]
    2016-10-18 1de2495dm19(暂无匿称)

    继续关注

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1921142, encodeId=22f51921142cc, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Dec 15 14:04:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822159, encodeId=e169182215903, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Sep 05 06:04:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959846, encodeId=4d25195984679, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 14 18:04:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780694, encodeId=60b01e80694c8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Dec 10 08:04:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869587, encodeId=258c186958e71, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 22 07:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151766, encodeId=2c1b151e666b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:29 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151765, encodeId=dd83151e6592, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:23 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149566, encodeId=1b87149566c9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:09 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149565, encodeId=3d7114956507, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:04 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252146, encodeId=e440125214688, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Oct 18 05:04:00 CST 2016, time=2016-10-18, status=1, ipAttribution=)]
    2016-10-18 1de2495dm19(暂无匿称)

    继续学习

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1921142, encodeId=22f51921142cc, content=<a href='/topic/show?id=6bfa58133ef' target=_blank style='color:#2F92EE;'>#新发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58133, encryptionId=6bfa58133ef, topicName=新发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Thu Dec 15 14:04:00 CST 2016, time=2016-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822159, encodeId=e169182215903, content=<a href='/topic/show?id=b8611021308a' target=_blank style='color:#2F92EE;'>#髓细胞白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102130, encryptionId=b8611021308a, topicName=髓细胞白血病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Tue Sep 05 06:04:00 CST 2017, time=2017-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959846, encodeId=4d25195984679, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Apr 14 18:04:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780694, encodeId=60b01e80694c8, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Sat Dec 10 08:04:00 CST 2016, time=2016-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869587, encodeId=258c186958e71, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jan 22 07:04:00 CST 2017, time=2017-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151766, encodeId=2c1b151e666b, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=146, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:29 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=151765, encodeId=dd83151e6592, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=117, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Fri Oct 28 20:25:23 CST 2016, time=2016-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149566, encodeId=1b87149566c9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:09 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=149565, encodeId=3d7114956507, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0df71676643, createdName=1de2495dm19(暂无匿称), createdTime=Tue Oct 18 21:07:04 CST 2016, time=2016-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252146, encodeId=e440125214688, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Tue Oct 18 05:04:00 CST 2016, time=2016-10-18, status=1, ipAttribution=)]
    2016-10-18 yxch36

相关资讯

Sci Rep:孕妇高果糖饮食可能对胎儿有不利影响

怀孕期间高果糖饮食可能会导致胎盘缺陷以及限制胎儿的生长,这无形中增加了婴儿以后的健康风险。不过,通过给予小鼠别嘌醇后发现,这似乎能够缓解孕妇的这种习惯带来的对胎儿不利影响。调查的结果提示高果糖摄入的产妇进行产前筛查是必要的。该研究结果发表在自然出版集团下属期刊《Scientific Reports》上。果糖是水果和蜂蜜中天然存在的一种糖类。糖果工业中已经将果糖玉米糖浆作为添加剂使用了几十年。果糖在

AM J OBSTET GYNECOL:孕期果糖摄入过多,宝宝患心血管病风险增加

德州加尔维斯敦大学医疗中心(UTMB)的研究人员指出,大量摄入果糖对几代人都有不利影响。 UTMB的研究人员发现,相比喝水的怀孕小鼠而言,当怀孕的小鼠喝加入果糖的水后,它们的后代患心脏病的风险更高。研究结果发表在the American Journal of Obstetrics and Gynecology。 这项研究结果可能对全球民众都有影响,因为大部分的加工食品和碳酸饮料中都含有果糖糖浆和其

JACC:减少含糖食品和饮料的摄入,肥胖和心血管几率大大降低

据发表在《美国心脏病学会杂志》的研究表明,约有一半的美国人每天都要喝含糖饮料,这回导致民众肥胖,并导致患病风险增加。原因部分因为饮料提供的能量不够,所以,人们往往在进食的时候饮用饮料,所以会导致增重的出现。美国盛产高果糖玉米糖浆等甜味剂,对食品和饮料生产商而言,这已成为一种代替蔗糖的更廉价的添加剂。尽管在过去10年里,民众饮用含糖饮料略有减少,但是高果糖玉米糖浆依旧是美国饮食中糖添加剂的最普遍最广

J Hepatology:常喝含糖饮料会引起脂肪肝?!

来自Tufts大学Jean Mayer USDA人类衰老营养研究中心(USDA HRNCA)的研究人员发现,每天喝含糖饮料的习惯可能会引起非酒精性脂肪肝(NAFLD)。此项研究结果近日在线发表于Journal of Hepatology杂志上。 非酒精性脂肪肝是在肝脏有脂肪的大量堆积,但与饮酒无关。这类脂肪肝可由超声,计算机断层扫描,核磁共振成像及组织活检诊断。在美国,约25%的人患有此类的

APT:果糖和乳糖不耐受及吸收不良检测

  果糖和乳糖不耐受及吸收不良与不同功能性胃肠病症状之间的相关性仍不清楚。近日,瑞典的Wilder-Smith对果糖和乳糖不耐受及吸收不良进行了研究,并研究了其与功能性胃肠病中的临床胃肠道症状以及非临床胃肠道症状之间的相关性。另外,研究团队对饮食干预转归进行了评价。研究指出,果糖和乳糖不耐受在功能性胃肠病中常见,与非临床胃肠道症状增加相关,不过与特异性功能性胃肠病亚型不相关。Wilder-Smit

Diabetes Res Clin Pr:TID儿童应该减少果糖的摄入

以往的研究显示,在成人,膳食果糖的高消耗引起血脂异常和血压升高,但在青少年,这方面的数据很少,特别是对那些处于心血管疾病(CVD)高风险的青少年。在1型糖尿病(T1D)青少年的多样化人群中,为了验证果糖摄入与CVD危险因素的关系。来自美国辛辛那提大学医学中心的Sarah C Couch教授及其团队进行了一项研究,该研究发现TID儿童,特别是那些伴有临界甘油三脂或高甘油三脂的儿童,应该减少果糖的摄入

Baidu
map
Baidu
map
Baidu
map